This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD hours. CPD dashboard

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD hours. Upgrade to Pro

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD hours. CPD dashboard

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD hours. Upgrade to Pro

Islatravir–lenacapavir

Authoring team

Overview

  • investigational once-weekly oral single-tablet antiretroviral regimen for the maintenance treatment of virologically suppressed HIV-1 in adults.
  • developed jointly by Gilead Sciences and Merck & Co. as the first once-weekly oral option for HIV treatment.

Mechanism of action

  • Islatravir (ISL) is a nucleoside reverse transcriptase translocation inhibitor (NRTTI) that blocks viral reverse transcriptase translocation, resulting in immediate and delayed chain termination.
  • Lenacapavir (LEN) is a first-in-class HIV-1 capsid inhibitor that disrupts essential capsid-mediated steps throughout the viral replication cycle, including nuclear import, viral assembly and capsid release.
  • combination provides dual-target antiviral activity with non-overlapping resistance profiles.

Dosage and administration

  • administered orally once weekly as a fixed-dose combination tablet containing 2 mg islatravir and 300 mg lenacapavir.
  • lower dose of islatravir (2 mg) was selected following early trial findings to avoid total lymphocyte and CD4+ T-cell count drops seen at higher doses.

Efficacy and safety

  • Phase 3 ISLEND-1 and ISLEND-2 trials demonstrated that switching to once-weekly ISL/LEN was non-inferior to continuing once-daily oral regimens (including Biktarvy) at maintaining HIV-1 RNA <50 copies/mL at week 48.
  • CD4+ T-cell and total lymphocyte counts remained stable through week 48 without dose-limiting lymphopenia at the 2 mg dose.
  • adverse event profile was comparable to standard daily oral therapy; most frequently reported events were mild headache and nausea.

References:

  1. Rockstroh JK, Ramgopal MN, Curran Fàbregas A, et al.; ISLEND-1 Study Team. Phase 3 trial of weekly oral islatravir–lenacapavir for HIV-1 treatment (ISLEND-1). N Engl J Med. 2026 Oct;395(13):1299-1309. doi: 10.1056/NEJMoa2607973.
  2. Gilead Sciences & Merck & Co. Investigational once-weekly oral HIV treatment regimen of islatravir and lenacapavir maintained virological suppression in adults with HIV (Phase 3 ISLEND-1 and ISLEND-2 primary endpoint results).
  3. Colson AE, Crofoot GE, Ruane PJ, et al. Safety and efficacy of once-weekly oral islatravir plus lenacapavir in virologically suppressed adults with HIV-1: 48-week results. Presented at: HIV Drug Therapy Glasgow. J Int AIDS Soc. 2024 Nov;27(Suppl 6):e26370. doi: 10.1002/jia2.26370.

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.